FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer By Ogkologos - April 8, 2026 5 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer EMA Recommends Extension of Therapeutic Indications for Asciminib NHS England Lung Cancer Screening Programme Demonstrates that it is Feasible and Scalable for Reaching High-Risk and Underserved Populations MOST POPULAR FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma November 13, 2025 Woman Helps Students With Special Needs Achieve Success After Graduation December 23, 2021 For People with Inherited Risk of Stomach Cancer, Gastrectomy Has Lasting... January 12, 2024 How Being an Athlete Prepared Me for My Cancer Experience August 9, 2022 Load more HOT NEWS Virchow: The Largest Foundation Model for Computational Pathology To Date Approval of Elahere Expands Treatment Options for Some Advanced Ovarian Cancers Incidence, Relative Risk and Risk Factors for Chronic Comorbidities in Long-Term... EMA Recommends Granting a Conditional Marketing Authorisation for Idecabtagene Vicleucel
